SUPPORT LINE

0300 111 1234

Tolvaptan

Read here the history of Tolvaptan.

To access the latest papers published on Tolvaptan, please visit PubMed website. (The search terms used to show this page of results were 'tolvaptan' AND 'polycystic kidney disease'.)

JINARC® (tolvaptan) approved in Europe

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive

On 28 May, 2015, the first-ever drug therapy for adults with ADPKD, was approved in Europe.

JINARC® - the brand name of the drug we know more commonly as tolvaptan - was developed by Otsuka Pharmaceutical Co Ltd. The company was granted marketing authorisation for JINARC® (tolvaptan) based on the findings of the pivotal Phase III randomised, double-blind and placebo-controlled TEMPO 3:4 trial – the largest clinical study conducted in ADPKD to date.

Click here for more information about Tolvaptan.

Print Email

0
0
0
s2sdefault

Tolvaptan Trial Results Announced

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive

At the American Society of Nephrology (ASN) meeting on 3 November 2012, Dr Vicente Torrres from the Mayo Clinic, together with research collaborators, reported the results of a 3 year global study known as TEMPO - Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease Outcomes.

Continue Reading

Print Email

0
0
0
s2sdefault

Latest Tweets

RT @NHSOrganDonor: “The fulfilment is when you see a transplanted kidney come alive in a recipient who has been waiting for a new lease of…

PKD Charity UK PKD Charity UK

PKD Charity is a Member of

  • Fundraising Regulator Website
  • Visit The Information Standard website
  • Visit PKD International website
  • Visit Ciliopathy Alliance website
  • Visit the Genetic Alliance UK website
  • Rare Disease UK Website
  • National Voices Website
  • Specialised Healthcare Alliance Website
  • FEDERG Website
  • Visit EURORDIS website